



December 12 2005

Richmond Hill, Ontario

Prolenium Medical Technologies is excited to announce formal Health Canada approval for its new line of Hyaluronic Acid Dermal Fillers: Revanesse, Revanesse Ultra and ReDexis. Prolenium is confident that the high concentration of cross linked Hyaluronic acid will provide the Canadian physician and patient with a superior quality, efficacious, low cost alternative to traditional dermal fillers. With the Revanesse product line, patients can expect to achieve not only augmentation, but also rejuvenation of the dermis.

Product breakdown:

Revanesse: A clear, biodegradable, cross linked HA gel filler. Revanesse is best used to fill superficial imperfections in the dermis such as fine lines, forehead wrinkles, crow's feet, peri-oral lines and small folds.

Revanesse Ultra: This high viscosity, clear, biodegradable, cross linked HA gel filler is a longer lasting filler used for smoothing out deep wrinkles and folds. The use of high viscosity HA makes Revanesse Ultra ideal for lip augmentation.

ReDexis: With an implant life of up to 24 months, ReDexis is the longest lasting of the three fillers. ReDexis is a clear, biodegradable, cross linked HA gel filler with Dextranomer beads. These positively charged beads stimulate the formation of soft tissue. ReDexis is indicated for medium to deep sized wrinkles and folds and is ideal for chin/cheek augmentation.

About Prolenium

Prolenium Medical Technologies, an innovator in the manufacturing of cosmetic injectables and cosmetic surgery products, was founded in 2002 and has since aggressively sought after the medical aesthetic market developing lines of dermal fillers, implants, serums, facial surgery products and injectables. Current products available for sale in Canada include the Revanesse family of products.

Prolenium Medical Technologies is an ISO 13485:2003 registered company